NCT06779851View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

BPT567

Immunocytokine infusion

Trial Locations (6)

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

28078

RECRUITING

Carolina BioOncology Institute, Huntersville

49546

RECRUITING

Start Midwest, Grand Rapids

85260

RECRUITING

Honor Health Research Institute, Scottsdale

97213

RECRUITING

Providence Cancer Institute, Portland

07601

RECRUITING

Hackensack Meridian John Theurer Cancer Center, Hackensack

Sponsors
All Listed Sponsors
lead

Bright Peak Therapeutics Inc

INDUSTRY

NCT06779851 - A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter